Avacta Group plc (GB:AVCT) has released an update.
Avacta Group plc, a life sciences company specializing in cancer treatments and diagnostics, will unveil its unaudited interim results for the first half of 2024 on September 30. Shareholders and potential investors are invited to attend an online presentation by CEO Christina Coughlin on the same day, where they can submit questions and engage with the company’s progress. The results and presentation will also be accessible on Avacta’s website, highlighting their proprietary platforms aimed at optimizing cancer drug delivery.
For further insights into GB:AVCT stock, check out TipRanks’ Stock Analysis page.
